Session Time: 8:30am-9:45am
Presentation Time: 8:45am-9:00am
Location: Veterans Auditorium
*Purpose: An international, double-blinded, randomised, paired phase 3 trial designed to determine the effect on 1-year graft function of continuous oxygenated (HMPO) vs non-oxygenated hypothermic machine perfusion (HMP) in controlled DCD kidneys from donors aged 50 years or older.
*Methods: At randomisation, one kidney from each donor was assigned to HMPO, the other to HMP. Kidneys were pumped immediately after retrieval until transplantation. The primary endpoint was estimated glomerular filtration rate (eGFR) at 1 year post-transplant (CKD-EPI) with 90% power at α=0.05 to detect a 8 ml/min/1.73m² difference. A pre-specified sensitivity analysis accounted for cases where no eGFR at 1 year was available due to graft loss (eGFR imputed by 10 mL/min/1.73m²) or patient death with functioning graft (last known eGFR carried forward). Secondary endpoints were delayed graft function, primary nonfunction, graft loss, and patient death. The primary analysis was performed according to intention to treat.
*Results: Belgium, the Netherlands, and part of the UK randomised 197 kidney pairs (median donor age 56 (range: 50-78) years), of which 106 were successfully machine perfused and transplanted (median recipient age 61 (21-79) years). Median total warm ischemia time was 28.5 (8-114) minutes and cold time was 11 (4.6-27.6) hours in HMPO and 10.3 (3.5-27.1) hours in HMP. Kidneys were pumped for 6.9 (1.7-24.3) vs 7.4 (1.3-23.8) hours. For the primary analysis, 83 pairs were eligible for inclusion (23 pairs excluded due to all-cause graft failure of at least 1 kidney). No difference in eGFR at 1 year was observed between HMPO vs HMP (mean(SE): 50.5(2.1) vs 46.7(1.8) mL/min/1.73m², p=0.12). However, sensitivity analysis, accounting for all-cause graft failure, showed a higher eGFR in HMPO (47.6(1.9) vs 42.6(2.0) mL/min/1.73m², p=0.035). Graft loss was significantly lower after HMPO; other secondary outcomes including patient death were similar between the two groups (Table).
*Conclusions: This first randomised controlled trial comparing HMPO with HMP suggests that oxygenation improves 1 year kidney graft function when accounting for the beneficial effect on graft survival.
|HMPO (n=106)||HMP (n=106)||p-value|
|Primary nonfunction||3 (2.8%)||5 (4.7%)||0.48|
|Delayed graft function||38 (35.8%)||38 (35.8%)||0.99|
|Graft loss||3 (2.8%)||11 (10.4%)||0.021|
|Patient death||7 (6.6%)||8 (7.5%)||0.80|
To cite this abstract in AMA style:Jochmans I, Hofker HS, Davies L, Knight S, Pirenne J, Ploeg RJ. Oxygenated Hypothermic Machine Perfusion of Kidneys Donated after Circulatory Death: An International Randomised Controlled Trial [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/oxygenated-hypothermic-machine-perfusion-of-kidneys-donated-after-circulatory-death-an-international-randomised-controlled-trial/. Accessed June 14, 2021.
« Back to 2019 American Transplant Congress